ANCA Vasculitis - Pulmonary Renal Syndrome Initial Management

Key Points

• Pulmonary-renal syndrome with rapidly progressive kidney injury is an organ-threatening emergency.
• Check anti-GBM antibodies because overlap disease changes plasma-exchange decisions.
• Kidney biopsy is highly informative but should not create a dangerous treatment delay in fulminant disease.
• Induction therapy uses glucocorticoids plus rituximab or cyclophosphamide.
• Reduced glucocorticoid exposure is preferred when disease severity allows.
• Plasma exchange is selective, not routine for every ANCA vasculitis patient.
• Diffuse alveolar hemorrhage can occur without hemoptysis.
• Provide infection prophylaxis and maintenance therapy planning from the start.

Algorithm

1. Recognize active urine sediment, rising creatinine, pulmonary infiltrates, hemoptysis/hypoxemia, or systemic small-vessel vasculitis features.
2. Stabilize oxygenation and hemodynamics and assess need for ICU/nephrology care.
3. Obtain CBC, renal panel, urinalysis/sediment, urine protein, PR3/MPO ANCA, anti-GBM, complements, cultures, and chest imaging.
4. Arrange kidney biopsy promptly when feasible and bronchoscopy if alveolar hemorrhage/infection remains uncertain.
5. Begin severe-disease induction with glucocorticoids plus rituximab or cyclophosphamide after urgent infection assessment.
6. Consider plasma exchange only for guideline-supported high-risk scenarios or anti-GBM overlap.
7. Provide Pneumocystis and other prophylaxis appropriate to the immunosuppressive regimen.
8. Transition to remission-maintenance therapy and longitudinal kidney, lung, relapse, and toxicity monitoring.

Clinical Synopsis & Reasoning

Pulmonary-renal syndrome should be suspected when hematuria, proteinuria, rising creatinine, RBC casts, pulmonary infiltrates, hemoptysis, hypoxemia, or falling hemoglobin occur together. ANCA-associated vasculitis includes granulomatosis with polyangiitis and microscopic polyangiitis, and can also involve ENT disease, mononeuritis multiplex, purpura, scleritis, constitutional symptoms, and other organs. Hemoptysis may be absent in diffuse alveolar hemorrhage, so unexplained bilateral infiltrates and anemia in a vasculitis-compatible patient deserve attention.

Initial testing includes urinalysis with microscopy, urine protein, creatinine/eGFR, CBC, ESR/CRP, ANCA with PR3/MPO specificity, anti-GBM antibodies, complements, chest imaging, cultures and infection testing. Kidney biopsy is highly valuable for diagnosis, chronicity, and prognosis when feasible, but treatment of rapidly progressive organ-threatening disease should not be dangerously delayed. Bronchoscopy can support diffuse alveolar hemorrhage and exclude infection when the diagnosis is uncertain. ANCA positivity is not synonymous with vasculitis and can occur with infection, drugs, and other inflammatory disease; conversely, a minority of clinically compatible cases are ANCA negative.

Treatment Strategy & Disposition

Severe ANCA vasculitis is induced with glucocorticoids plus rituximab or cyclophosphamide. KDIGO 2024 supports either agent, with choice influenced by prior therapy, fertility, relapse history, PR3 disease, access, infection risk, and kidney function. Reduced-dose glucocorticoid regimens are preferred when possible to decrease serious infection without sacrificing disease control. Avacopan, a C5a receptor inhibitor, can reduce glucocorticoid exposure in selected patients and is incorporated into contemporary strategies.

Plasma exchange is not routine for all ANCA vasculitis after PEXIVAS, but may be considered in selected patients with very severe kidney failure, rapidly rising creatinine, dialysis dependence, severe diffuse alveolar hemorrhage with hypoxemia, or overlap with anti-GBM disease, using guideline and specialist judgment. Provide Pneumocystis prophylaxis during high-intensity immunosuppression when indicated, screen for hepatitis/TB according to therapy, and update vaccinations. After remission, maintenance therapy commonly uses rituximab or another immunosuppressive strategy. Relapse monitoring is clinical; ANCA titers alone should not determine escalation.

Epidemiology / Risk Factors

• ANCA vasculitis is uncommon but carries high early morbidity from kidney failure, pulmonary hemorrhage, infection, and treatment toxicity.
• PR3-positive disease generally has higher relapse risk than MPO-positive disease.
• Older age and advanced kidney dysfunction worsen prognosis.
• Infection is a major early cause of death during induction therapy.

Investigations

High Risk Features

Pharmacology

Prognosis / Complications

• Rapid treatment can preserve kidney and pulmonary function, but chronic kidney disease may persist despite immunologic remission.
• Relapse is common enough that maintenance therapy and long-term follow-up are required.
• Dialysis at presentation does not automatically mean kidneys cannot recover.
• Treatment-related infection and cumulative immunosuppressive toxicity are major determinants of outcome.

Patient Education / Counseling

• Explain that immunosuppression is urgent because kidney scarring and pulmonary injury can progress quickly.
• Review fever and infection precautions and when to seek urgent assessment during induction.
• Discuss fertility preservation before cyclophosphamide when time and clinical stability permit.
• Avoid live vaccines during significant immunosuppression and coordinate routine vaccines before therapy when feasible.
• Report hemoptysis, increasing dyspnea, reduced urine, edema, new neuropathy, or purpura promptly.

Notes

The key management tension is speed versus diagnostic precision. Fulminant pulmonary-renal syndrome can destroy kidney function within days, but infection can imitate vasculitis and become lethal if immunosuppression is given blindly. Parallel evaluation is therefore essential: cultures and imaging are obtained while nephrology/rheumatology prepare biopsy and treatment.

Plasma exchange should no longer be automatic simply because creatinine is high. Contemporary KDIGO guidance reserves it for selected patients at the highest risk or with anti-GBM overlap, taking into account kidney trajectory, dialysis status, pulmonary hemorrhage severity, and infection risk.

References

1. KDIGO 2024 Clinical Practice Guideline for ANCA-Associated Vasculitis — Link